Helus Pharma Inc.(HELP)

Medical - Pharmaceuticals · Toronto, ON

$10.99-0.43 (-3.77%)

Delayed quote: Oct 6, 2026, 12:15 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:17:03.039Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:17:03.039Z.

Quote observation: 2026-10-06T16:15:14.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 681,205,259
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 166,165,362
TTM operating EBITDA · period ending 2026-06-30: -177,046,735

FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

HELP EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

HELP Competitors' EV/EBITDA Ratio

HELP

Helus Pharma Inc.

Current

Market Cap

$681.21M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANNX

Annexon, Inc.

vs HELP

Market Cap

$681.58M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVR

Anteris Technologies Global Corp.

vs HELP

Market Cap

$690.28M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs HELP

Market Cap

$672.27M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs HELP

Market Cap

$670.50M

EV/EBITDA Ratio

26.27x

TTM Avg

12.95x

3Y Avg

19.43x

5Y Avg

199.83x

OABI

OmniAb, Inc.

vs HELP

Market Cap

$648.75M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OLMA

Olema Pharmaceuticals, Inc.

vs HELP

Market Cap

$714.33M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COLL

Collegium Pharmaceutical, Inc.

vs HELP

Market Cap

$718.54M

EV/EBITDA Ratio

2.86x

TTM Avg

4.78x

3Y Avg

5.46x

5Y Avg

7.57x

AVBP

ArriVent BioPharma, Inc.

vs HELP

Market Cap

$659.73M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVTX

Avalo Therapeutics, Inc.

vs HELP

Market Cap

$717.52M

EV/EBITDA Ratio

N/A

TTM Avg

867.40x

3Y Avg

862.35x

5Y Avg

862.35x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Helus Pharma Inc. (HELP)	$681.21M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$681.58M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$690.28M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$672.27M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$670.50M	26.27x	12.95x	19.43x	199.83x
OmniAb, Inc. (OABI)vs ›	$648.75M	N/A	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$714.33M	N/A	N/A	N/A	N/A
Collegium Pharmaceutical, Inc. (COLL)vs ›	$718.54M	2.86x	4.78x	5.46x	7.57x
ArriVent BioPharma, Inc. (AVBP)vs ›	$659.73M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$717.52M	N/A	867.40x	862.35x	862.35x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics